TRDA Quote, Financials, Valuation and Earnings

EyePoint Plc has a net margin of -3014.94% compared to Entrada Therapeutics, Inc.'s net margin of -6183.44%. Entrada Therapeutics, Inc.'s return on equity of -38.39% beat EyePoint Plc's return on equity of -79.15%.

Entrada Therapeutics, Inc. has a consensus price target of $20.00, signalling upside risk potential of 71.23%. On the other hand EyePoint Plc has an analysts' consensus of $36.33 which suggests that it could grow by 97.89%. Given that EyePoint Plc has higher upside potential than Entrada Therapeutics, Inc., analysts believe EyePoint Plc is more attractive than Entrada Therapeutics, Inc..

Entrada Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison EyePoint Plc has a beta of 1.725, suggesting its more volatile than the S&P 500 by 72.48%.

Entrada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EyePoint Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entrada Therapeutics, Inc. pays -- of its earnings as a dividend. EyePoint Plc pays out -- of its earnings as a dividend.

Entrada Therapeutics, Inc. quarterly revenues are $1.3M, which are larger than EyePoint Plc quarterly revenues of $966K. Entrada Therapeutics, Inc.'s net income of -$39.2M is higher than EyePoint Plc's net income of -$59.7M. Notably, Entrada Therapeutics, Inc.'s price-to-earnings ratio is 7.16x while EyePoint Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entrada Therapeutics, Inc. is 19.01x versus 29.75x for EyePoint Plc. Usually stocks with elevated PS ratios are considered overvalued.

Kodiak Sciences, Inc. has a net margin of -3014.94% compared to Entrada Therapeutics, Inc.'s net margin of --. Entrada Therapeutics, Inc.'s return on equity of -38.39% beat Kodiak Sciences, Inc.'s return on equity of -201.8%.

Entrada Therapeutics, Inc. has a consensus price target of $20.00, signalling upside risk potential of 71.23%. On the other hand Kodiak Sciences, Inc. has an analysts' consensus of $35.50 which suggests that it could grow by 29.75%. Given that Entrada Therapeutics, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Entrada Therapeutics, Inc. is more attractive than Kodiak Sciences, Inc..

Entrada Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kodiak Sciences, Inc. has a beta of 2.613, suggesting its more volatile than the S&P 500 by 161.277%.

Entrada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kodiak Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entrada Therapeutics, Inc. pays -- of its earnings as a dividend. Kodiak Sciences, Inc. pays out -- of its earnings as a dividend.

Entrada Therapeutics, Inc. quarterly revenues are $1.3M, which are larger than Kodiak Sciences, Inc. quarterly revenues of --. Entrada Therapeutics, Inc.'s net income of -$39.2M is higher than Kodiak Sciences, Inc.'s net income of -$61.5M. Notably, Entrada Therapeutics, Inc.'s price-to-earnings ratio is 7.16x while Kodiak Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entrada Therapeutics, Inc. is 19.01x versus -- for Kodiak Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Repligen Corp. has a net margin of -3014.94% compared to Entrada Therapeutics, Inc.'s net margin of 6.71%. Entrada Therapeutics, Inc.'s return on equity of -38.39% beat Repligen Corp.'s return on equity of 2.4%.

Entrada Therapeutics, Inc. has a consensus price target of $20.00, signalling upside risk potential of 71.23%. On the other hand Repligen Corp. has an analysts' consensus of $186.28 which suggests that it could grow by 49.06%. Given that Entrada Therapeutics, Inc. has higher upside potential than Repligen Corp., analysts believe Entrada Therapeutics, Inc. is more attractive than Repligen Corp..

Entrada Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Repligen Corp. has a beta of 1.145, suggesting its more volatile than the S&P 500 by 14.545%.

Entrada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Repligen Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entrada Therapeutics, Inc. pays -- of its earnings as a dividend. Repligen Corp. pays out -- of its earnings as a dividend.

Entrada Therapeutics, Inc. quarterly revenues are $1.3M, which are smaller than Repligen Corp. quarterly revenues of $197.9M. Entrada Therapeutics, Inc.'s net income of -$39.2M is lower than Repligen Corp.'s net income of $13.3M. Notably, Entrada Therapeutics, Inc.'s price-to-earnings ratio is 7.16x while Repligen Corp.'s PE ratio is 144.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entrada Therapeutics, Inc. is 19.01x versus 9.58x for Repligen Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals, Inc. has a net margin of -3014.94% compared to Entrada Therapeutics, Inc.'s net margin of 36.91%. Entrada Therapeutics, Inc.'s return on equity of -38.39% beat Vertex Pharmaceuticals, Inc.'s return on equity of 22.97%.

Entrada Therapeutics, Inc. has a consensus price target of $20.00, signalling upside risk potential of 71.23%. On the other hand Vertex Pharmaceuticals, Inc. has an analysts' consensus of $535.56 which suggests that it could grow by 10.19%. Given that Entrada Therapeutics, Inc. has higher upside potential than Vertex Pharmaceuticals, Inc., analysts believe Entrada Therapeutics, Inc. is more attractive than Vertex Pharmaceuticals, Inc..

Entrada Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals, Inc. has a beta of 0.307, suggesting its less volatile than the S&P 500 by 69.319%.

Entrada Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entrada Therapeutics, Inc. pays -- of its earnings as a dividend. Vertex Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Entrada Therapeutics, Inc. quarterly revenues are $1.3M, which are smaller than Vertex Pharmaceuticals, Inc. quarterly revenues of $3.2B. Entrada Therapeutics, Inc.'s net income of -$39.2M is lower than Vertex Pharmaceuticals, Inc.'s net income of $1.2B. Notably, Entrada Therapeutics, Inc.'s price-to-earnings ratio is 7.16x while Vertex Pharmaceuticals, Inc.'s PE ratio is 31.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entrada Therapeutics, Inc. is 19.01x versus 10.39x for Vertex Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.